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 Depressive disorders have been with man since the beginning of recorded 
history. In the Bible, King David, as well as Job, suffered from this affliction. 
Hippocrates referred to depression as melancholia, which literally means black 
bile. Black bile, along with blood, phlegm, and yellow bile were the four humors 
(fluids) that accounted for the basic medical physiology of that time. Depression 
has been portrayed in literature and the arts for hundreds of years, but what do 
we mean today when we refer to a depressive disorder? In the 19th century, 
depression was seen as an inherited weakness of temperament. In the first half 
of the 20th century, Freud linked the development of depression to guilt and 
conflict. John Cheever, the author and a modern sufferer of depressive disorder, 
wrote of conflict and experiences with his parents as influencing his development 
of depression. In the 1950s and 60s, depression was divided into two types, 
endogenous and neurotic. Endogenous means that the depression comes from 
within the body, perhaps of genetic origin, or comes out of nowhere. Neurotic or 
reactive depression has a clear environmental precipitating factor, such as the 
death of a spouse, or other significant loss, such as the loss of a job. In the 
1970s and 80s, the focus of attention shifted from the cause of depression to its 
effects on the afflicted people. Currently, researchers are focusing their effort in 
understanding the biological causes of this condition in order to develop new 
treatments. 
Depressive disorders are a huge public health problem. Depression costs the 
United States huge amounts of direct costs, which are the treatment costs, and 
indirect costs, such as lost productivity and absenteeism. In a major medical 
study, depression caused significant problems in the functioning of those affected 
more often than did arthritis, hypertension, chronic lung disease, and diabetes, 
and in two categories of problems, as often as coronary artery disease. 
Depression can increase the risks for developing coronary artery disease, HIV, 
asthma, and some other medical illnesses. Furthermore, it can increase the 
morbidity (illness) and mortality (death) from these conditions. Depression is 
usually first identified in a primary-care setting, not in a mental health 
practitioner's office. Moreover, it often assumes various disguises, which causes 
depression to be frequently under-diagnosed. In spite of clear research evidence 
and clinical guidelines regarding therapy, depression is often under-treated. 
Hopefully, this situation can change for the better. For full recovery from a mood 
disorder, regardless of whether there is a precipitating factor or it seems to come 
out of the blue, treatments with medications and/or brain stimulation therapy and 
psychotherapy are necessary.  
What are the causes of depression? 
Some types of depression run in families, indicating that a biological 
vulnerability to depression can be inherited. This seems to be the case especially 
with bipolar disorder. Studies have been done of families in which members of 
each generation develop bipolar disorder. The investigators found that those with 
the illness have a somewhat different genetic makeup than those who do not 
become ill. Apparently, additional factors, possibly a stressful environment, are 
involved in its onset. 
An external event often seems to initiate an episode of depression. Thus, a 
serious loss, chronic illness, difficult relationship, financial problem, or any 
unwelcome change in life patterns can trigger a depressive episode. Very often, 
a combination of genetic, psychological, and environmental factors is involved in 
the onset of a depressive disorder. 
Nothing in the universe is as complex and fascinating as the human brain. The 
over 100 chemicals that circulate in the brain are known as neurochemicals or 
neurotransmitters. Much of our research and knowledge, however, has focused 
on four of these neurochemical systems: norepinephrine, serotonin, dopamine, 
and acetylcholine. After new discoveries are made, it is possible that these four 
neurochemicals will be viewed as the "black bile, yellow bile, phlegm, and blood" 
of the 20th century. 
Different neuropsychiatric illnesses seem to be associated with an 
overabundance or a lack of some of these neurochemicals in certain parts of the 
brain.  The depressive disorders appear to be associated with altered brain 
serotonin and norepinephrine systems. Both of these neurochemicals are lower 
in depressed people. Please note that I specified, "associated with" instead of, 
"caused by." I made this distinction because we really don't know whether low 
levels of neurochemicals in the brain cause depression or whether depression 
causes low levels of neurochemicals in the brain. 
What we do know is certain medications that alter the levels of norepinephrine or 
serotonin can alleviate the symptoms of depression. Some medicines that affect 
both of these neurochemical systems appear to perform even better or faster. 
Other medications that treat depression primarily affect the other neurochemical 
systems. The most powerful treatment for depression, electroconvulsive therapy 
(ECT), is certainly not specific to any particular neurotransmitter system. Rather, 
ECT, by causing a seizure, produces a generalized brain activity that probably 
releases massive amounts of all of the neurochemicals. 
 
Antidepressant  Medications              
 
Selective serotonin reuptake inhibitors (SSRIs) are medications that 
increase the amount of the neurochemical serotonin in the brain. (Remember 
that brain serotonin levels are low in depression.) As their name implies, the 
SSRIs work by selectively inhibiting (blocking) serotonin reuptake in the brain. 
This block occurs at the synapse, the place where brain cells (neurons) are 
connected to each other. Serotonin is one of the chemicals in the brain that 
carries messages across these connections (synapses) from one neuron to 
another. The SSRIs work by keeping the serotonin present in high concentrations 
in the synapses. These drugs do this by preventing the reuptake of serotonin 
back into the sending nerve cell. The reuptake of serotonin is responsible for 
turning off the production of new serotonin. Therefore, the serotonin message 
keeps on coming through. This, in turn, helps arouse (activate) cells that have 
been deactivated by depression, and relieves the depressed person's symptoms. 
The most common side effects are nausea, diarrhea, agitation, insomnia, and 
headache. However, these side effects generally go away within the first month 
of SSRI use. Some patients experience sexual side effects, such as decreased 
sexual desire (decreased libido), delayed orgasm, or an inability to have an 
orgasm. Some patients experience tremors with SSRIs. The so-called 
serotonergic (meaning caused by serotonin) syndrome is a serious neurologic 
condition associated with the use of SSRIs. It is characterized by high fevers, 
seizures, and heart rhythm disturbances. This condition is very rare and has 
been reported only in very ill psychiatric patients taking multiple psychiatric 
medications. 
Tricyclic antidepressants (TCAs) were developed in the 1950s and 60s 
to treat depression. They are called tricyclic antidepressants because their 
chemical structures consist of three chemical rings. TCAs work mainly by 
increasing the level of norepinephrine in the brain synapses, although they also 
may affect serotonin levels. Doctors often use TCAs to treat moderate to severe 
depression. TCAs are safe and generally well tolerated when properly prescribed 
and administered. However, TCAs can cause life-threatening heart rhythm 
disturbances. Thus, some TCAs can produce dry mouth, constipation, and 
dizziness upon standing. The dizziness results from low blood pressure that 
occurs upon standing (orthostatic hypotension). Anticholinergic side effects can 
also aggravate narrow angle glaucoma, urinary obstruction due to benign 
prostate hypertrophy, and cause delirium in the elderly.   
Electroconvulsive therapy (ECT) 
In the ECT procedure, an electric current is passed through the brain to 
produce controlled convulsions (seizures). ECT is useful for certain patients, 
particularly for those who cannot take or are not responding to antidepressants, 
have severe depression, or are at a high risk for suicide. ECT often is effective in 
cases where antidepressant medications do not provide sufficient relief of 
symptoms. This procedure probably works, as previously mentioned, by a 
massive neurochemical release in the brain due to the controlled seizure. Highly 
effective, ECT relieves depression within one to two weeks after beginning 
treatments. After ECT, some patients will continue to have maintenance ECT, 
while others will return to antidepressant medications. 
In recent years, the technique of ECT has been much improved. The treatment is 
given in the hospital under anesthesia so that people receiving ECT do not feel 
pain. Most patients undergo six to 10 treatments. An electrical current is passed 
through the brain to cause a controlled seizure, which typically lasts for 20 to 90 
seconds. The patient is awake in five to 10 minutes. The most common side 
effect is short-term memory loss, which resolves quickly. After the initial course of 
treatment, ECT can be safely done as an outpatient procedure. 
 
A new potential 
One very promising avenue for influencing the living brain has emerged in 
the last decade, based on the use of pulsed magnetic fields. The skull is a good 
insulator, and past efforts to alter the electrical activity happening inside it have 
required high voltages, with little opportunity for fine control or focus of the 
effects. Consider instead how easily a magnet under a wooden tabletop can 
move a pin on the surface - magnetic fields pass almost unaffected through 
insulators, including the skull. 
It is easy in principle to get a magnetic field to produce electrical effects: simply 
change the field over time, and any charge-carriers (like the ions in the cells of 
the brain) will be influenced to flow, creating an induced current. However, 
affecting neurons inside the head requires a lot of magnetic force to be changed 
very quickly, and the technology to do this has only been around for about a 
decade. The first trans-cranial magnetic stimulation (TMS) machines, capable of 
delivering a pulse every three seconds, were developed as diagnostic aids for 
neurologists. For instance, the motor part of the brain can be stimulated, inducing 
a twitch of the thumb, which tells a neurologist that the intervening nerve 
pathways are intact. Machines are now available which can give up to 100 stimuli 
per second (rapid-rate TMS, or rTMS) and their effects are more interesting. 
Among a wide range of possibilities, it is believed that rTMS may have a place in 
the treatment of some mental illnesses. It is a non-invasive technique, apparently 
free of serious side-effects, capable of modifying the activity of specific brain 
areas. 
How it works 
The magnetic fields used in TMS are produced by passing current through 
a hand-held coil, whose shape determines the properties and size of the field. 
The coil is driven by a machine which switches the large current necessary in a 
very precise and controlled way, at rates up to 50 cycles per second in rTMS. 
The coil is held on the scalp - no actual contact is necessary - and the magnetic 
field passes through the skull and into the brain. Small induced currents can then 
make brain areas below the coil more or less active, depending on the settings 
used. 
In practice, TMS and rTMS are able to influence many brain functions, including 
movement, visual perception, memory, reaction time, speech and mood. The 
effects produced are genuine but temporary, lasting only a short time after actual 
stimulation has stopped. 
Safety issues 
Generally, TMS appears to be free from harmful effects. Research using 
animals and human volunteers has showed little effect on the body in general as 
a result of stimulation, and examination of brain tissue submitted to thousands of 
TMS pulses has shown no detectable structural changes. It is possible in unusual 
circumstances to trigger a seizure in normal patients, but a set of guidelines 
which virtually eliminate this risk are available. Research continues, but TMS is 
certainly free of obvious side-effects like those of electro-convulsive therapy 
(ECT), which still makes quite an impact on patients despite refinements in 
technique. 
TMS / rTMS in the treatment of mental illness 
Many mental illnesses can be demonstrated to stem from the abnormal 
behaviour of particular brain regions. It is believed that some mental disorders 
are the result of nerve cells being over- or under-excitable (in other words, it is 
too easy or too difficult for them to "fire" and work properly). In this context, 
successful psychiatric treatment is achieved by modifying these cells behaviour. 
The range of effects produced by TMS are a clear indication of its potential to 
work in this way. 
Of course, TMS could only be used to treat diseases whose functional causes 
are understood. Recent progress in understanding the mechanisms behind 
depression, obsessive-compulsive disorder, and neurological diseases like 
Parkinson's and Huntington's, offers some hope in these areas. It must be 
stressed that most of the excitement about TMS is based on potential rather than 
proven effectiveness, but research is being conducted around the world. For 
instance, there is reason to believe that rTMS could replace some ECT 
treatments currently used for severely depressed patients. Groups in Germany, 
the United States and Israel have reported positive results from using TMS and 
rTMS to treat depressed patients. The prospect of replacing ECT with a near-
painless treatment, which does not require anaesthesia, would change these 
people's lives remarkably. 
Ever-happy Mice 
 
To investigate the mechanisms of action of rTMS we gave TMS to mice 
for five days, then we analysed their brains for evidence of plasticity and cell 
proliferation. We showed that rTMS enhanced Long term potentiation (LTP), a 
leading molecular model of plasticity in all areas of the brain tested, by modifying 
key glutamate receptors so that they stayed active for longer. We saw large 
increases in the proliferation of stem cells in the dentate gyrus hippocampus. 
These cells divide throughout life and are now believed to play a crucial role in 
memory and mood regulation. 
Thus, is our study we highlighted the mechanism of action of rTMS. 
Our results will help researchers to design more effective brain stimulation 
treatments for drug-resistant refractory depression. 
  
 
 
 
 
 
 
 
